Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track AXSM with free AI briefings, catalyst countdowns, and dilution alerts.

AXSM — Axsome Therapeutics, Inc.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$305.1M Cash on Hand

46.5mo Cash Runway

9.4% Short Interest

🧪 Upcoming Trial Catalysts

2026-07-01 · Phase 2 — Recruiting — Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
2026-12-01 · Phase 3 — Recruiting — Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Dis
2026-12-01 · Phase 3 — Enrolling — Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
2026-12-01 · Phase 2 — Recruiting — Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
2028-03-01 · Phase 3 — Recruiting — Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research D
2028-05-01 · Phase 3 — Enrolling — Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

📊 Drug Pipeline

Drug	Indication	Phase	Status
AXS-05	Major Depressive Disorder	PHASE4	RECRUITING
Solriamfetol	Excessive Daytime Sleepiness	PHASE4	COMPLETED
Solriamfetol 75 MG	Insomnia	PHASE4	COMPLETED
Solriamfetol Oral Tablet	Excessive Sleepiness	PHASE4	TERMINATED
Bupropion	Major Depressive Disorder	PHASE4	RECRUITING
AXS-14 (Esreboxetine)	Fibromyalgia	PHASE3	RECRUITING
Solriamfetol 300 mg	Binge-Eating Disorder	PHASE3	RECRUITING
Solriamfetol 150 MG	Binge-Eating Disorder	PHASE3	RECRUITING
Rizatriptan	Migraine	PHASE3	COMPLETED
Meloxicam	Migraine	PHASE3	COMPLETED

💰 Cash Runway & Dilution Risk

AXSM holds $305.1M in cash and burns about $19.7M/quarter from operations, giving an estimated runway of 46.5 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for AXSM free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-06-11	JEFFS ROGER	Sale	$14.4M
2026-06-11	JEFFS ROGER	Sale	$14.5M
2026-06-10	JEFFS ROGER	Purchase	$0
2026-06-10	JEFFS ROGER	Sale	$0
2026-06-10	Saad Mark E	Purchase	$0

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2026-04-30	—	sNDA	+14.6%	+12.9%	+21%

Browse all historical PDUFA outcomes →

Get the full AXSM picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for AXSM and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z